Oxitropium

Summary

Oxitropium (CHEMBL4297364) is a phase-3 clinical-stage small molecule; indicated across 1 condition including chronic obstructive pulmonary disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 332.4 Da · C19H26NO4+

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297364
Name	Oxitropium
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	6917866
Molecular formula	C19H26NO4+
Molecular weight	332.4
InChIKey	NVOYVOBDTVTBDX-AGUVMIOSSA-N

SMILES: CC[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C

IUPAC name: [(1R,2R,4S,5S)-9-ethyl-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate

Also known as: Oxitropium, OXITROPIUM, oxitropium

Parent form; salt/anhydrous children: CHEMBL4297109

Patent coverage: 13 distinct patent families (29 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M1.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CHRM2	8.52	AC50	3	nM	CHEMBL_ACT_25195483
CHRM1	8.52	AC50	3	nM	CHEMBL_ACT_25209990

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
chronic obstructive pulmonary disease	3	MONDO:0005002	EFO:0000341

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02172807	PHASE3	COMPLETED	Efficacy and Safety of Ba679BR Powder Inhalation in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).